Editorial Staff

Drug Rebates: How Pharmacy Benefit Managers Manipulate Price & Limit Choice

/0 Comments/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Join host Joe Selvaggi and his guest Dr. Bill Smith as they discuss the complex incentive structure between drug manufacturers, health plans, and pharmacy benefit managers. In this episode, they focus on how drug rebates work and how a system intended to optimize value may actually deliver higher costs and fewer choices. Joe and Bill also use this framework to speculate on the price of a COVID-19 vaccine, and who will likely pay for it.

Guest:

Dr. William Smith is Visiting Fellow in Life Sciences at Pioneer Institute. Bill has recently published a working paper entitled, Growing Drug Rebates Hurt Both Consumers and our Healthcare System.  He is here to share with us his findings on how drug rebates work and how they affect which drugs we are prescribed and how much we pay. Bill has spent ten years at Pfizer as Vice President of Public Affairs and Policy, has been President of a medical device company,  and has had senior staff positions with U.S. Congressional House leadership, the White House, and in the Governor’s office in Massachusetts. He earned his PhD at the Catholic University of America and a bachelor’s degree from Georgetown University.

Get new episodes of Hubwonk in your inbox!

Related Content

Mortgage’s New Normal: Guide to Better Borrowing Amidst Higher Rates

Joe Selvaggi talks with mortgage expert, Trip Miller of Cambridge Savings Bank, about mortgage rates and trends and explores best practices for finding a mortgage structure that suits individual buyers’ needs.

Medicaid’s Massive Miasma: Taming Beacon Hill’s Burgeoning Budget Beast

Marc Joffe, a state policy analyst at the Cato Institute, talks about his research on Medicaid's cost and size. They explore how Massachusetts can control spending growth while protecting other priorities.

Baystate Budget Blues: Declining Revenue Causes Concern

Joe Selvaggi engages in a conversation with Pioneer Institute’s Eileen McAnneny, Senior Fellow for Economic Opportunity, to analyze the status of the 2024 budget. They compare actual revenue and spending with pre-July 1 estimates, investigating potential reasons for any surpluses or shortfalls. They also dive into policy implications for legislators as they approach fiscal 2025.

Smothering Gas Exports: President Sides with Environmentalists Over Environment

Dr. Benjamin Zycher, a senior fellow at the American Enterprise Institute, talks on the impact of President Biden's executive order to halt liquefied natural gas export approvals. He explores potential economic impacts, the response from trading partners, and the negligible effect on climate.

U.S. Manufacturing Health: Does the U.S. Need an Industrial Policy?

Scott Lincicome from the Cato Institute discusses the U.S. manufacturing industry, international trade, and industrial policy. He dispels the myth of manufacturing decline, highlighting sector evolution and productivity. The conversation moves to industrial policy, emphasizing the need for targeted protection and cautioning against broad subsidization due to potential inefficiencies.

Challenging Government Prerogatives: SCOTUS Reconsiders Deference to Executive Agencies

Joe Selvaggi engages in a conversation with legal scholar Ilya Shapiro from the Manhattan Institute regarding the Loper Bright Enterprises Supreme Court case that questions the Chevron Doctrine. This doctrine instructs judges to defer to government agencies in situations where laws are silent or unclear.

Harvard’s Sullied Halo: Journalists Teach Lesson on Plagiarism

Joe Selvaggi talks with investigative reporter Chris Brunet about his role investigating and exposing former Harvard President Claudine Gay’s academic plagiarism, a story that lead to her eventual resignation.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.

Boston’s Building Bargain: Coaxing Commercial Conversions to Condos

Joe Selvaggi discusses the strategic goals of Boston's Downtown Office to Residential Conversion Pilot Program with Arthur Jemison, the head of BPDA planning. The aim is to transform underutilized offices in Downtown into vibrant places to live.

SCOTUS Wealth Tax: Are Appreciated Assets Income?

Joe Selvaggi talks with CATO Institute constitutional scholar Thomas Berry about the recently argued Moore v. U.S.A. case, which challenges the idea that income must be realized before it can be taxed.

Busting Big Business: Antitrust Comes for Google and Big Sandwich

Joe Selvaggi talks with Dr. Brian Albrecht, an economists with the International Center for Law and Economics. They separate fact from fiction when it comes to the public’s and politicians’ concerns over allegedly anti-consumer practices of big business and discuss when antitrust action by the federal government is justified.

Supreme Oral Arguments: Do Gun Rights Rest on Responsible Behavior

Joe Selvaggi engages in a conversation with constitutional scholar Attorney Clark Neily to explore the oral arguments presented in the US Supreme Court case USA v Rahimi. The discussion delves into the intricate examination of behavioral history and the legal processes involved in restricting an individual from owning a firearm.

Powering Earth’s Unplugged: Overcoming Barriers to Electricity Benefits Billions

Joe Selvaggi talks with energy journalist Robert Bryce about his views on the benefits and barriers to bringing cheap, abundant electricity to the nearly 4 billion people without access.

Peace Through Compassion

In a conversation between Joe Selvaggi and George Mason law professor Ilya Somin, Somin presents his viewpoint on the moral and strategic case for allowing free emigration of Palestinian refugees from the conflict zone to bolster Israel’s fight against Hamas terrorism.